CD8A and neoplasm: Mutant KRAS (mKRAS) has been previously studied as a potential target of cancer vaccines, and clinical studies have demonstrated the successful generation of CD4+ and CD8+ αβ T cell responses with reactivity against allogeneic or autologous mKRAS tumor cell lines15–18.